Follow up: palmitic acid ester of tetrahydrocannabinol (THC) and palmitic acid diester of 11-hydroxy-THC - unsuccessful search for additional THC metabolites.


Journal

Drug metabolism and personalized therapy
ISSN: 2363-8915
Titre abrégé: Drug Metab Pers Ther
Pays: Germany
ID NLM: 101653409

Informations de publication

Date de publication:
22 03 2021
Historique:
received: 05 09 2020
accepted: 21 12 2020
entrez: 19 8 2021
pubmed: 20 8 2021
medline: 2 4 2022
Statut: epublish

Résumé

In a previous investigation we searched for the occurrence of palmitic acid ester compounds of delta9-tetrahydrocannabinol (THC) and its primary metabolite 11-hydroxy-delta9-THC (11-OH-THC) in human body fluids and tissues (THC palmitic acid monoester [THC-Pal] and 11-OH-THC palmitic acid diester [11-OH-THC-DiPal]). As those esters could not be detected in various human body fluids (e.g. blood) or tissues (e.g. adipose tissue) we extended the investigation analyzing adipose tissue samples of mice previously given synthetic THC or a cannabis extract. In total, 48 adipose tissue samples previously tested positive for THC by means of a liquid chromatographic triple quadrupole mass spectrometric (LC-QQQ-MS) method were analyzed for the presence of THC-Pal and 11-OH-THC-DiPal by means of LC-QQQ-MS. THC-Pal and 11-OH-THC-DiPal were not detected among the adipose tissue samples analyzed despite the presence of high THC concentrations within the adipose tissue. THC concentrations in adipose tissue were in a range of approximately 7-2,595 ng/g (median: 468 ng/g, average: 704 ng/g). A (site-specific) synthesis of 11-OH-THC palmitic acid monoesters (11-hydroxy-delta9-THC-1-palmitate and 11-palmitoyloxy-delta9-THC) still remains to be done. After synthesis of these monoesters, their presence in the body fluids and tissues after THC administration should be investigated.

Identifiants

pubmed: 34412174
pii: dmpt-2020-0151
doi: 10.1515/dmpt-2020-0151
doi:

Substances chimiques

Esters 0
Palmitic Acid 2V16EO95H1
Dronabinol 7J8897W37S

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

199-203

Informations de copyright

© 2021 Walter de Gruyter GmbH, Berlin/Boston.

Références

Huestis, MA. Human cannabinoid pharmacokinetics. Chem Biodivers 2007;4:1770–804. https://doi.org/10.1002/cbdv.200790152.
Johansson, E, Norén, K, Sjövall, J, Halldin, MM. Determination of Δ1‐tetrahydrocannabinol in human fat biopsies from marihuana users by gas chromatography–mass spectrometry. Biomed Chromatogr 1989;3:35–8. https://doi.org/10.1002/bmc.1130030109.
Kreuz, DS, Axelrod, J. Delta-9-tetrahydrocannabinol: localization in body fat. Science 1973;179:391–3. https://doi.org/10.1126/science.179.4071.391.
Leighty, EG. Metabolism and distribution of cannabinoids in rats after different methods of administration. Biochem Pharmacol 1973;22:1613–21. https://doi.org/10.1016/0006-2952(73)90028-2.
Leighty, EG, Fentiman, AF, Foltz, RL. Long-retained metabolites of delta9- and delta8-tetrahydrocannabinols identified as novel fatty acid conjugates. Res Commun Chem Pathol 1976;14:13–28.
Kraemer, M, Broecker, S, Diehl, BWK, Madea, B, Hess, C. Palmitic acid ester of tetrahydrocannabinol (THC) and palmitic acid diester of 11-hydroxy-THC - unsuccessful search for additional THC metabolites in human body fluids and tissues. Forensic Sci Int 2019;294:86–95. https://doi.org/10.1016/j.forsciint.2018.11.005.
Leuschner, JT, Harvey, DJ, Bullingham, RE, Paton, WD. Pharmacokinetics of delta 9-tetrahydrocannabinol in rabbits following single or multiple intravenous doses. Drug Metab Dispos 1986;14:230–8.
Yisak, W, Agurell, S, Lindgren, J‐E, Widman, M. In vivo metabolites of cannabinol identified as fatty acid conjugates. J Pharm Pharmacol 1978;30:462–4. https://doi.org/10.1111/j.2042-7158.1978.tb13292.x.
Leighty, EG. Distribution, pharmacokinetics and hydrolysis of a fatty acid conjugated cannabinoid given acutely or chronically to rats. Res Commun Subst 1980;1:49–63.

Auteurs

Michael Kraemer (M)

Institute of Legal Medicine, University of Bonn, University Hospital Bonn, Bonn, Germany.

Cornelius Hess (C)

Institute of Legal Medicine, University of Mainz, Forensic Toxicology, Mainz, Germany.

Alexandra Maas (A)

Institute of Legal Medicine, University of Bonn, University Hospital Bonn, Bonn, Germany.

Burkhard Madea (B)

Institute of Legal Medicine, University of Bonn, University Hospital Bonn, Bonn, Germany.

Andras Bilkei-Gorzo (A)

Institute of Molecular Psychiatry, Medical Faculty, University of Bonn, Bonn, Germany.

Prakash Nidadavolu (P)

Institute of Molecular Psychiatry, Medical Faculty, University of Bonn, Bonn, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH